| 货号 | HY373016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | Research Grade Biosimilar |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | Pancreatic carcinoma marker protein GA733-1, Tumor-associated calcium signal transducer 2, M1S1, TROP2, TACSTD2, Cell surface glycoprotein Trop-2, GA733-1, Membrane component chromosome 1 surface marker 1 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >98% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G, purified from cell culture supernatant. |
| Accession号 | P09758 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS,pH7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | IMMU-132,hRS7-SN-38,hRS7-SN-38-ADC,hRS7-[CL-SN-38],CAS:1796566-95-4 |
| 背景 | Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer. |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
SEC-HPLC detection for Research Grade Sacituzumab.
Detects Human TACSTD2/TROP2 in direct ELISAs.
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
